Virbac stock gains 2.64 percent as Bernstein raises target

Virbac stock (ISIN FR0000031577) was trading at EUR 311.50 at Lang & Schwarz on September 29, 2026, up 2.64 percent versus the Xetra close of EUR 303.50 on September 28, 2026. The move follows a stronger first half and a fresh analyst upgrade.

Half-year growth supports guidance

Virbac reported on September 17, 2026, that first-half revenue reached EUR 768.0 million, up 7.40 percent at constant exchange rates and scope from H1 2025. Companion animal revenue grew 10.00 percent, while farm animal revenue increased 6.70 percent.

Adjusted EBIT rose to EUR 144.2 million from EUR 135.0 million in H1 2025, lifting the adjusted EBIT margin to 18.80 percent from 18.30 percent. Consolidated net income increased 5.90 percent to EUR 87.1 million, giving the results a broader earnings base than revenue growth alone.

Bernstein raises its target

As Investing.com reported on September 21, 2026, Bernstein upgraded Virbac to Outperform from Market Perform and raised its price target to EUR 426.00 from EUR 419.00. The new target stands 36.76 percent above the Lang & Schwarz price of EUR 311.50, making margin expansion the central valuation argument.

The company confirmed its 2026 revenue growth range of 5.50 percent to 7.50 percent at constant exchange rates and scope. The first-half result positions Virbac at the upper end of that range, while its adjusted recurring operating income margin guidance remains targeted at 17.00 percent.

Virbac stock trades above prior close

Virbac stock was trading at EUR 311.50 at Lang & Schwarz on September 29, 2026, at 11:08 a.m. CEST. The price was up 2.64 percent against the Xetra close of EUR 303.50 on September 28, 2026, while the 52-week range stood at EUR 297.00 to EUR 389.50.

More news and analyses on Virbac stock